Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Kenneth, Kwok"'
Autor:
Grace C. Wright, Eduardo Mysler, Kenneth Kwok, Mary Jane Cadatal, Rebecca Germino, Arne Yndestad, Cassandra D. Kinch, Alexis Ogdie
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1135-1164 (2024)
Abstract Introduction Racial disparities in disease activity, clinical outcomes, and treatment survival persist despite advancements in rheumatoid arthritis (RA) therapies and clinical management. In this post hoc analysis of pooled data from the tof
Externí odkaz:
https://doaj.org/article/7fc4cc04798247339219428e07071d32
Autor:
Arne Yndestad, Maya H Buch, Carol A Connell, Kenneth Kwok, Ted Mikuls, Deepak L Bhatt, Jon T Giles, Christina Charles-Schoeman, Gary G Koch, Edward Nagy, Steven Ytterberg, Hyejin Jo, Karim Richard Masri
Publikováno v:
RMD Open, Vol 10, Iss 2 (2024)
Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in Oral
Externí odkaz:
https://doaj.org/article/ecd72b34dd1d469b9cb491e81996c9d4
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-15 (2023)
Abstract Background This study sought to evaluate the efficacy and safety of tofacitinib in patients with rheumatoid arthritis with distinct treatment histories. Methods Pooled phase II/III trial data from patients who received tofacitinib 5 or 10 mg
Externí odkaz:
https://doaj.org/article/7911c65fbf6142c1825230c24b2584dd
Autor:
Adrian Ciurea, Oliver Distler, Kenneth Kwok, Hyejin Jo, Lisy Wang, Tim Killeen, Caroline Ospelt, Mojca Frank Bertoncelj
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-11 (2023)
Abstract Background Rheumatoid arthritis (RA) has a variable impact on different synovial joints, with inflammation being more commonly observed in some joints than others. Emerging evidence suggests that the anatomical variation in pathophysiology c
Externí odkaz:
https://doaj.org/article/9479b52939a04c16b0a79b727ac1a436
Autor:
Gerd R. Burmester, Laura C. Coates, Stanley B. Cohen, Yoshiya Tanaka, Ivana Vranic, Edward Nagy, Irina Lazariciu, All-shine Chen, Kenneth Kwok, Lara Fallon, Cassandra Kinch
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 5, Pp 1255-1276 (2023)
Abstract Introduction The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in clinical studies of ≤ 4 and 9.5 years, respectively. Post-marketing surveillance (PMS) data for tofacitinib from spo
Externí odkaz:
https://doaj.org/article/34b105e8c7c24f45a0dae2316f33af1c
Autor:
Gerd R. Burmester, Laura C. Coates, Stanley B. Cohen, Yoshiya Tanaka, Ivana Vranic, Edward Nagy, Irina Lazariciu, All-shine Chen, Kenneth Kwok, Lara Fallon, Cassandra Kinch
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 1, Pp 221-222 (2023)
Externí odkaz:
https://doaj.org/article/099e14f76fec48319dad1e2044b6fc13
Autor:
Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 2, Pp 357-373 (2022)
Abstract Introduction This post hoc analysis evaluated influenza adverse events (AEs) across rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA) tofacitinib clinical programs. Methods Available data from phase 1, randomi
Externí odkaz:
https://doaj.org/article/636def3d7be64a6abbfb716f2f5fce89
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lars E. Kristensen, Bruce Strober, Denis Poddubnyy, Ying-Ying Leung, Hyejin Jo, Kenneth Kwok, Ivana Vranic, Dona L. Fleishaker, Lara Fallon, Arne Yndestad, Dafna D. Gladman
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 15 (2023)
Background: Tofacitinib is a Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and has been investigated for psoriasis (PsO). Objectives: This post hoc analysis examined baseline cardiovascular (CV) disease risk and its associatio
Externí odkaz:
https://doaj.org/article/a4fdb740116042e0a5f1302e3f61e5d5
Autor:
Jürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis, Joel Silverfield, Ketti Terry, Koshika Soma, Chris Mojcik, Ryan DeMasi, Sander Strengholt, Kenneth Kwok, Irina Lazariciu, Lisy Wang, Stanley Cohen
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-18 (2019)
Abstract Background Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA). Method
Externí odkaz:
https://doaj.org/article/cbd75ed150f44a9ea233626add2ba876